Letters to the Editor

To the Editor

In reference to the commentary “No easy answers to address drug shortages,” in the Aug. 25, 2019, issue of Ocular Surgery News, we, HUB Pharmaceuticals USA, would like to offer a correction.

HUB Pharmaceuticals USA is the exclusive U.S. distributor for our indocyanine green (NDC 17238-424-06). We have been the distributor since 2010. Indocyanine green USP is used in ophthalmology for retinal angiography.

HUB Pharmaceuticals has and continues to maintain full stocks of our ICG. We provide the product through our network of ophthalmic distributors nationwide, as well as via the wholesaler distribution channel, including AmerisourceBergen, Cardinal Health and McKesson Drug.

We would appreciate it if this information would be included as a response to this commentary. There have been many rumors as to the availability of some of these products, and we would like to correct the record.

Ron Clarke
Vice President, Sales & Business Development
HUB Pharmaceuticals USA

In reference to the commentary “No easy answers to address drug shortages,” in the Aug. 25, 2019, issue of Ocular Surgery News, we, HUB Pharmaceuticals USA, would like to offer a correction.

HUB Pharmaceuticals USA is the exclusive U.S. distributor for our indocyanine green (NDC 17238-424-06). We have been the distributor since 2010. Indocyanine green USP is used in ophthalmology for retinal angiography.

HUB Pharmaceuticals has and continues to maintain full stocks of our ICG. We provide the product through our network of ophthalmic distributors nationwide, as well as via the wholesaler distribution channel, including AmerisourceBergen, Cardinal Health and McKesson Drug.

We would appreciate it if this information would be included as a response to this commentary. There have been many rumors as to the availability of some of these products, and we would like to correct the record.

Ron Clarke
Vice President, Sales & Business Development
HUB Pharmaceuticals USA